Literature DB >> 22464363

Predictive model accuracy in estimating last Δ9-tetrahydrocannabinol (THC) intake from plasma and whole blood cannabinoid concentrations in chronic, daily cannabis smokers administered subchronic oral THC.

Erin L Karschner1, David M Schwope, Eugene W Schwilke, Robert S Goodwin, Deanna L Kelly, David A Gorelick, Marilyn A Huestis.   

Abstract

BACKGROUND: Determining time since last cannabis/Δ9-tetrahydrocannabinol (THC) exposure is important in clinical, workplace, and forensic settings. Mathematical models calculating time of last exposure from whole blood concentrations typically employ a theoretical 0.5 whole blood-to-plasma (WB/P) ratio. No studies previously evaluated predictive models utilizing empirically-derived WB/P ratios, or whole blood cannabinoid pharmacokinetics after subchronic THC dosing.
METHODS: Ten male chronic, daily cannabis smokers received escalating around-the-clock oral THC (40-120 mg daily) for 8 days. Cannabinoids were quantified in whole blood and plasma by two-dimensional gas chromatography-mass spectrometry.
RESULTS: Maximum whole blood THC occurred 3.0 h after the first oral THC dose and 103.5h (4.3 days) during multiple THC dosing. Median WB/P ratios were THC 0.63 (n=196), 11-hydroxy-THC 0.60 (n=189), and 11-nor-9-carboxy-THC (THCCOOH) 0.55 (n=200). Predictive models utilizing these WB/P ratios accurately estimated last cannabis exposure in 96% and 100% of specimens collected within 1-5h after a single oral THC dose and throughout multiple dosing, respectively. Models were only 60% and 12.5% accurate 12.5 and 22.5h after the last THC dose, respectively.
CONCLUSIONS: Predictive models estimating time since last cannabis intake from whole blood and plasma cannabinoid concentrations were inaccurate during abstinence, but highly accurate during active THC dosing. THC redistribution from large cannabinoid body stores and high circulating THCCOOH concentrations create different pharmacokinetic profiles than those in less than daily cannabis smokers that were used to derive the models. Thus, the models do not accurately predict time of last THC intake in individuals consuming THC daily. Published by Elsevier Ireland Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22464363      PMCID: PMC3461265          DOI: 10.1016/j.drugalcdep.2012.03.005

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  18 in total

1.  Delirium following ingestion of marijuana present in chocolate cookies.

Authors:  Charles André; Jorge A Jaber-Filho; Rafael M A Bento; Lúcia M P Damasceno; Francisco R Aquino-Neto
Journal:  CNS Spectr       Date:  2006-04       Impact factor: 3.790

2.  A case series of patients using medicinal marihuana for management of chronic pain under the Canadian Marihuana Medical Access Regulations.

Authors:  Mary E Lynch; Judee Young; Alexander J Clark
Journal:  J Pain Symptom Manage       Date:  2006-11       Impact factor: 3.612

3.  Delta9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THC.

Authors:  Eugene W Schwilke; David M Schwope; Erin L Karschner; Ross H Lowe; William D Darwin; Deanna L Kelly; Robert S Goodwin; David A Gorelick; Marilyn A Huestis
Journal:  Clin Chem       Date:  2009-10-15       Impact factor: 8.327

4.  Cannabis psychosis following bhang ingestion.

Authors:  H R Chaudry; H B Moss; A Bashir; T Suliman
Journal:  Br J Addict       Date:  1991-09

5.  Blood cannabinoids. II. Models for the prediction of time of marijuana exposure from plasma concentrations of delta 9-tetrahydrocannabinol (THC) and 11-nor-9-carboxy-delta 9-tetrahydrocannabinol (THCCOOH)

Authors:  M A Huestis; J E Henningfield; E J Cone
Journal:  J Anal Toxicol       Date:  1992 Sep-Oct       Impact factor: 3.367

6.  Implications of plasma Delta9-tetrahydrocannabinol, 11-hydroxy-THC, and 11-nor-9-carboxy-THC concentrations in chronic cannabis smokers.

Authors:  Erin L Karschner; Eugene W Schwilke; Ross H Lowe; W David Darwin; Ronald I Herning; Jean Lud Cadet; Marilyn A Huestis
Journal:  J Anal Toxicol       Date:  2009-10       Impact factor: 3.367

7.  Intra- and intersubject whole blood/plasma cannabinoid ratios determined by 2-dimensional, electron impact GC-MS with cryofocusing.

Authors:  Eugene W Schwilke; Erin L Karschner; Ross H Lowe; Ann M Gordon; Jean Lud Cadet; Ronald I Herning; Marilyn A Huestis
Journal:  Clin Chem       Date:  2009-03-05       Impact factor: 8.327

8.  Cannabinoid concentrations in spot serum samples 24-48 hours after discontinuation of cannabis smoking.

Authors:  Gisela Skopp; Lucia Pötsch
Journal:  J Anal Toxicol       Date:  2008-03       Impact factor: 3.367

9.  Comparison of cannabinoid pharmacokinetic properties in occasional and heavy users smoking a marijuana or placebo joint.

Authors:  Stefan W Toennes; Johannes G Ramaekers; Eef L Theunissen; Manfred R Moeller; Gerold F Kauert
Journal:  J Anal Toxicol       Date:  2008-09       Impact factor: 3.367

10.  Do Delta9-tetrahydrocannabinol concentrations indicate recent use in chronic cannabis users?

Authors:  Erin L Karschner; Eugene W Schwilke; Ross H Lowe; W David Darwin; Harrison G Pope; Ronald Herning; Jean L Cadet; Marilyn A Huestis
Journal:  Addiction       Date:  2009-10-05       Impact factor: 6.526

View more
  11 in total

1.  THC and CBD blood and brain concentrations following daily administration to adolescent primates.

Authors:  S L Withey; J Bergman; M A Huestis; S R George; B K Madras
Journal:  Drug Alcohol Depend       Date:  2020-06-18       Impact factor: 4.492

2.  Ultra-high performance liquid chromatography tandem mass-spectrometry for simple and simultaneous quantification of cannabinoids.

Authors:  Rohitash Jamwal; Ariel R Topletz; Bharat Ramratnam; Fatemeh Akhlaghi
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2017-02-06       Impact factor: 3.205

Review 3.  A marijuana-drug interaction primer: Precipitants, pharmacology, and pharmacokinetics.

Authors:  Emily J Cox; Neha Maharao; Gabriela Patilea-Vrana; Jashvant D Unadkat; Allan E Rettie; Jeannine S McCune; Mary F Paine
Journal:  Pharmacol Ther       Date:  2019-05-07       Impact factor: 12.310

4.  Extended plasma cannabinoid excretion in chronic frequent cannabis smokers during sustained abstinence and correlation with psychomotor performance.

Authors:  Erin L Karschner; Madeleine J Swortwood; Jussi Hirvonen; Robert S Goodwin; Wendy M Bosker; Johannes G Ramaekers; Marilyn A Huestis
Journal:  Drug Test Anal       Date:  2015-06-11       Impact factor: 3.345

5.  Controlled vaporized cannabis, with and without alcohol: subjective effects and oral fluid-blood cannabinoid relationships.

Authors:  Rebecca L Hartman; Timothy L Brown; Gary Milavetz; Andrew Spurgin; David A Gorelick; Gary Gaffney; Marilyn A Huestis
Journal:  Drug Test Anal       Date:  2015-08-10       Impact factor: 3.345

6.  Blood levels do not predict behavioral or physiological effects of Δ⁹-tetrahydrocannabinol in rhesus monkeys with different patterns of exposure.

Authors:  Brett C Ginsburg; Lenka Hruba; Armia Zaki; Martin A Javors; Lance R McMahon
Journal:  Drug Alcohol Depend       Date:  2014-03-19       Impact factor: 4.492

7.  Developing a phone-based measure of impairment after acute oral ∆9-tetrahydrocannabinol.

Authors:  Elisa Pabon; Harriet de Wit
Journal:  J Psychopharmacol       Date:  2019-08-13       Impact factor: 4.562

8.  Oral Administration of Cannabis and Δ-9-tetrahydrocannabinol (THC) Preparations: A Systematic Review.

Authors:  Lourdes Poyatos; Ana Pilar Pérez-Acevedo; Esther Papaseit; Clara Pérez-Mañá; Soraya Martin; Olga Hladun; Adrià Siles; Marta Torrens; Francesco Paolo Busardo; Magí Farré
Journal:  Medicina (Kaunas)       Date:  2020-06-23       Impact factor: 2.430

Review 9.  Pharmacokinetics of Cannabis and Its Derivatives in Animals and Humans During Pregnancy and Breastfeeding.

Authors:  Anaëlle Monfort; Ema Ferreira; Grégoire Leclair; Gregory Anton Lodygensky
Journal:  Front Pharmacol       Date:  2022-07-12       Impact factor: 5.988

10.  Validity of oral fluid test for Delta-9-tetrahydrocannabinol in drivers using the 2013 National Roadside Survey Data.

Authors:  Huiyan Jin; Sharifa Z Williams; Stanford T Chihuri; Guohua Li; Qixuan Chen
Journal:  Inj Epidemiol       Date:  2018-02-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.